Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.

Simcere, Hengrui, and Zai Lab are among the first Chinese pharma firms to report various forms of impact from the gathering storm of a national anti-corruption campaign launched in July in the healthcare and pharma sectors.

China- and US-based biotech LianBio is advancing three late-stage clinical assets in hopes that successful commercialization could lead to profitability and validate its in-licensing business model in a challenging environment.